These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 39067448

  • 1. Dissecting the neuroprotective interaction between the BH4 domain of BCL-w and the IP3 receptor.
    Tang SX, Camara CM, Franco JA, Pazyra-Murphy MF, Li Y, Godes M, Moyer BM, Bird GH, Segal RA, Walensky LD.
    Cell Chem Biol; 2024 Oct 17; 31(10):1815-1826.e5. PubMed ID: 39067448
    [Abstract] [Full Text] [Related]

  • 2. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor.
    Rong YP, Bultynck G, Aromolaran AS, Zhong F, Parys JB, De Smedt H, Mignery GA, Roderick HL, Bootman MD, Distelhorst CW.
    Proc Natl Acad Sci U S A; 2009 Aug 25; 106(34):14397-402. PubMed ID: 19706527
    [Abstract] [Full Text] [Related]

  • 3. Bcl-2 and IP3 compete for the ligand-binding domain of IP3Rs modulating Ca2+ signaling output.
    Ivanova H, Wagner LE, Tanimura A, Vandermarliere E, Luyten T, Welkenhuyzen K, Alzayady KJ, Wang L, Hamada K, Mikoshiba K, De Smedt H, Martens L, Yule DI, Parys JB, Bultynck G.
    Cell Mol Life Sci; 2019 Oct 25; 76(19):3843-3859. PubMed ID: 30989245
    [Abstract] [Full Text] [Related]

  • 4. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
    Monaco G, Vervliet T, Akl H, Bultynck G.
    Cell Mol Life Sci; 2013 Apr 25; 70(7):1171-83. PubMed ID: 22955373
    [Abstract] [Full Text] [Related]

  • 5. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
    Akl H, Vervloessem T, Kiviluoto S, Bittremieux M, Parys JB, De Smedt H, Bultynck G.
    Biochim Biophys Acta; 2014 Oct 25; 1843(10):2240-52. PubMed ID: 24768714
    [Abstract] [Full Text] [Related]

  • 6. Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl.
    Monaco G, Decrock E, Akl H, Ponsaerts R, Vervliet T, Luyten T, De Maeyer M, Missiaen L, Distelhorst CW, De Smedt H, Parys JB, Leybaert L, Bultynck G.
    Cell Death Differ; 2012 Feb 25; 19(2):295-309. PubMed ID: 21818117
    [Abstract] [Full Text] [Related]

  • 7. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
    Monaco G, La Rovere R, Karamanou S, Welkenhuyzen K, Ivanova H, Vandermarliere E, Di Martile M, Del Bufalo D, De Smedt H, Parys JB, Economou A, Bultynck G.
    FEBS J; 2018 Jan 25; 285(1):127-145. PubMed ID: 29131545
    [Abstract] [Full Text] [Related]

  • 8. The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP3 receptor channels.
    Ivanova H, Luyten T, Decrock E, Vervliet T, Leybaert L, Parys JB, Bultynck G.
    Cell Calcium; 2017 Mar 25; 62():41-46. PubMed ID: 28179071
    [Abstract] [Full Text] [Related]

  • 9. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
    Lavik AR, Zhong F, Chang MJ, Greenberg E, Choudhary Y, Smith MR, McColl KS, Pink J, Reu FJ, Matsuyama S, Distelhorst CW.
    Oncotarget; 2015 Sep 29; 6(29):27388-402. PubMed ID: 26317541
    [Abstract] [Full Text] [Related]

  • 10. Alpha-helical destabilization of the Bcl-2-BH4-domain peptide abolishes its ability to inhibit the IP3 receptor.
    Monaco G, Decrock E, Nuyts K, Wagner LE, Luyten T, Strelkov SV, Missiaen L, De Borggraeve WM, Leybaert L, Yule DI, De Smedt H, Parys JB, Bultynck G.
    PLoS One; 2013 Sep 29; 8(8):e73386. PubMed ID: 24137498
    [Abstract] [Full Text] [Related]

  • 11. Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2.
    Bittremieux M, La Rovere RM, Akl H, Martines C, Welkenhuyzen K, Dubron K, Baes M, Janssens A, Vandenberghe P, Laurenti L, Rietdorf K, Morciano G, Pinton P, Mikoshiba K, Bootman MD, Efremov DG, De Smedt H, Parys JB, Bultynck G.
    Cell Death Differ; 2019 Mar 29; 26(3):531-547. PubMed ID: 29899382
    [Abstract] [Full Text] [Related]

  • 12. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor.
    Rong YP, Barr P, Yee VC, Distelhorst CW.
    Biochim Biophys Acta; 2009 Jun 29; 1793(6):971-8. PubMed ID: 19056433
    [Abstract] [Full Text] [Related]

  • 13. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
    Akl H, Monaco G, La Rovere R, Welkenhuyzen K, Kiviluoto S, Vervliet T, Molgó J, Distelhorst CW, Missiaen L, Mikoshiba K, Parys JB, De Smedt H, Bultynck G.
    Cell Death Dis; 2013 May 16; 4(5):e632. PubMed ID: 23681227
    [Abstract] [Full Text] [Related]

  • 14. Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration.
    Pease-Raissi SE, Pazyra-Murphy MF, Li Y, Wachter F, Fukuda Y, Fenstermacher SJ, Barclay LA, Bird GH, Walensky LD, Segal RA.
    Neuron; 2017 Oct 11; 96(2):373-386.e6. PubMed ID: 29024661
    [Abstract] [Full Text] [Related]

  • 15. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4.
    Huang DC, Adams JM, Cory S.
    EMBO J; 1998 Feb 16; 17(4):1029-39. PubMed ID: 9463381
    [Abstract] [Full Text] [Related]

  • 16. Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones.
    Distelhorst CW.
    Biochim Biophys Acta Mol Cell Res; 2018 Nov 16; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
    [Abstract] [Full Text] [Related]

  • 17. Profiling of the Bcl-2/Bcl-X(L)-binding sites on type 1 IP(3) receptor.
    Monaco G, Beckers M, Ivanova H, Missiaen L, Parys JB, De Smedt H, Bultynck G.
    Biochem Biophys Res Commun; 2012 Nov 09; 428(1):31-5. PubMed ID: 23058917
    [Abstract] [Full Text] [Related]

  • 18. Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction.
    Zhong F, Harr MW, Bultynck G, Monaco G, Parys JB, De Smedt H, Rong YP, Molitoris JK, Lam M, Ryder C, Matsuyama S, Distelhorst CW.
    Blood; 2011 Mar 10; 117(10):2924-34. PubMed ID: 21193695
    [Abstract] [Full Text] [Related]

  • 19. Tracing the evolutionary history of Ca2+-signaling modulation by human Bcl-2: Insights from the Capsaspora owczarzaki IP3 receptor ortholog.
    Rosa N, Shabardina V, Ivanova H, Sebé-Pedrós A, Yule DI, Bultynck G.
    Biochim Biophys Acta Mol Cell Res; 2021 Nov 10; 1868(12):119121. PubMed ID: 34400171
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of Pro-apoptotic BAX by a noncanonical interaction mechanism.
    Barclay LA, Wales TE, Garner TP, Wachter F, Lee S, Guerra RM, Stewart ML, Braun CR, Bird GH, Gavathiotis E, Engen JR, Walensky LD.
    Mol Cell; 2015 Mar 05; 57(5):873-886. PubMed ID: 25684204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.